Satralizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany) and HIRA (South Korea) recommended or restricted satralizumab, while CIPM (Spain), CONITEC (Brazil) and DMC (Denmark), among others, did not recommend it.
The record spans 3.4 years, opening at G-BA (Germany) on 6 Jan 2022 and running to 12 Jun 2025.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), AWMSG (Wales) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for satralizumab, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 5 of 11 records date from 2023 or later.
Against its own class, satralizumab is an outlier: 38% of its decisive outcomes were positive, where molecules sharing ATC class L04A average 78%.
G-BA (Germany) was first to assess satralizumab, on 6 Jan 2022; CONITEC (Brazil) did not open a file until 13 May 2025 — a wide spread of 3.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 11 dated records fall in 2022 alone.
HIRA (South Korea) is the only agency to have returned to satralizumab, recording 2 separate entries.
10 of the 18 agencies in this archive hold a record for satralizumab.
The full ledger for satralizumab reads 5 not recommended, 3 recommended, 1 terminated and 1 non-submission, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 12 Jun 2025 | 항아쿠아포린 -4 항체 양성 시신경척수염 범주질환 | extension of coverage appropriate | source |
| CONITEC (Brazil) | 13 May 2025 | Tratamento de pacientes com distúrbio do espectro da neuromielite óptica. | not incorporated | source |
| NICE (England) | 27 Mar 2024 | NICE TA960 | terminated appraisal | source |
| SMC (Scotland) | 11 Mar 2024 | As a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patie… | not recommended | source |
| CIPM (Spain) | 24 Nov 2022 | SECRETARIA DE ESTADO DE SANIDAD 32 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicación terapéutica autorizada: Enspry… | not financed by the SNS · art. 92 d, e | source |
6 further decisions for satralizumab, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 11 decisions for satralizumab from 10 agencies, 2022 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.